bims-miptne Biomed News
on Mitochondrial permeability transition pore-dependent necrosis
Issue of 2026–11–01
sixteen papers selected by
Oluwatobi Samuel Adegbite, University of Liverpool



  1. Cells. 2026 Oct 10. pii: 1839. [Epub ahead of print]15(20):
      Disease-modifying neuroprotective therapies for traumatic brain injury (TBI), stroke, and age-related neurodegenerative disorders have proven elusive. Interest in mitochondrial outer membrane permeabilization mechanisms as a drug target evolved from the 1990s discovery of BAX/BAK-mediated mitochondrial cytochrome c release as an apoptotic cell death trigger. However, enthusiasm waned as subsequent findings revealed that apoptosis is not the dominant cell death mechanism in the mature brain. The more recent discovery of mitochondrial DNA (mtDNA) as an inflammatory trigger produced renewed interest in mitochondrial permeability pathways. In particular, the DNA-sensing molecule cGAS and its downstream effector STING were implicated in the pathogenesis of several neurodegenerative conditions, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and TBI. Nevertheless, these findings raised a puzzling question: how does mtDNA, which resides in the mitochondrial matrix surrounded by double membranes, escape to initiate inflammatory responses without triggering cytochrome c-dependent cell death? Here, we review the many proposed mechanisms for mtDNA release, including several that do not require mitochondrial membrane holes, and discuss advances toward pharmacological targeting of these pathways. Identification of the specific mtDNA efflux pathway(s) proximal to maladaptive neuroinflammatory responses may yield new treatment strategies for AD, TBI, and other neurological diseases.
    Keywords:  MDV; MLKL; NLRP3; STING; apoptosis; cGAS; inflammasome; mPTP; mitophagy; mtDNA
    DOI:  https://doi.org/10.3390/cells15201839
  2. Biochemistry (Mosc). 2026 Oct;91(10): 1951-1961
      Strong physiological activation of blood platelets leads to the emergence of a non-aggregatable procoagulant subpopulation characterized by the appearance of phosphatidylserine on the outer leaflet of the plasma membrane, providing a surface for coagulation reactions. The formation of procoagulant platelets is attributed to cyclophilin D-dependent opening of the mitochondrial permeability transition pore in response to mitochondrial calcium overload; however, the mechanisms of calcium entry and subsequent necrosis have not been definitively established. We used continuous flow cytometry to analyze the main stages of this process following platelet stimulation by monitoring cytosolic calcium dynamics (Fura Red), reactive oxygen species (ROS) levels (CM-H2DCFDA), plasma membrane integrity (calcein), mitochondrial potential [DiOC6(3)], fluorescent fibrinogen binding, and procoagulant activity (annexin V). Receptor stimulation induced procoagulant platelet formation through an intermediate platelet subpopulation characterized by depolarized mitochondria, but polarized plasma membrane and elevated phosphatidylserine. During the early activation (less than 5 min), ROS increased sharply in the subpopulation with elevated phosphatidylserine content and steadily increased in the non-procoagulant subpopulation; by 15 min, ROS levels were comparable between the two populations. Addition of the protonophore CCCP at any point during activation did not affect the formation of procoagulant platelets. However, CCCP addition during activation of platelets preincubated with the cyclophilin D inhibitor cyclosporin A resulted in explosive necrosis. CCCP also increased calcium concentrations in resting platelets. These data help explain the contradictory effects of CCCP on platelet necrosis and highlight the importance of the voltage-dependent calcium accumulation in mitochondria. They further suggest a significance of ROS in platelet necrosis, while the loss of membrane integrity appears to be a secondary process.
    Keywords:  activation; calcium; mitochondria; necrosis; platelets
    DOI:  https://doi.org/10.1134/S0006297926601966
  3. Nature. 2026 Oct 28.
      The heart possesses a dynamic capacity to oxidize a variety of fuels, including glucose and lactate, to meet its energetic demands under diverse dietary, exertion and injury stressors1. Oxidation of carbohydrate substrates is thought to converge on the cytosolic generation of pyruvate, which is transported by the mitochondrial pyruvate carrier (MPC) for entry into the tricarboxylic acid cycle2. Here we find that glucose-derived carbon is oxidized in mouse myocardium even when the MPC is genetically ablated. Using genetic and pharmacological tools, we demonstrate that lactate monocarboxylate transporter 1 (MCT1, encoded by Slc16a1) is required for the oxidation of glucose carbon by MPC-deficient myocardium. We further observe that MCT1, traditionally localized to the plasma membrane, also resides in the inner mitochondrial membrane of mouse and human cardiomyocytes. Together with matrix-localized LDHB, MCT1 enables mitochondrial lactate conversion to pyruvate and NADH, directly fueling the electron transport chain. Loss of MCT1 impairs lactate oxidation, disrupts metabolic flexibility and accelerates the development of heart failure with increased mortality after hyperactivation of the neurohormonal axis or ischemia-reperfusion injury. Thus, the existence of a parallel lactate-based pathway for carbohydrate oxidation can sustain cardiac energetics and maintain myocardial structure and function under diverse stress conditions.
    DOI:  https://doi.org/10.1038/s41586-026-11182-3
  4. Nat Cardiovasc Res. 2026 Oct 27.
      Mitofusin (MFN) 1 and MFN2 are large outer mitochondrial membrane GTPases. Dimerization of MFNs on adjacent mitochondria mediates mitochondrial fusion. MFN2, but not MFN1, also resides at the endoplasmic reticulum (ER)/sarcoplasmic reticulum (SR) membrane, and dimerization of MFNs on ER/SR and mitochondria tethers the two organelles. Here we report that cell-permeable peptides that perturb MFN conformations regulate myocardial infarct size by impacting ER/SR-mitochondria interactions and Ca2+ transfer independently of changes in mitochondrial fusion. MFN activators increase ER/SR-mitochondria proximity, promote ER/SR to mitochondria Ca2+ transfer and exacerbate infarct size in mice, with effects dependent on MFN2, but not MFN1, and on mitochondrial calcium uniporter, which transports Ca2+ into the mitochondrial matrix. Conversely, although ER/SR-mitochondria proximity is not affected, MFN inhibitors reduce mitochondrial Ca2+ transfer and infarct size, even when their administration is delayed until reperfusion. These findings demonstrate the feasibility of acutely modulating ER/SR-mitochondria interactions and Ca2+ dynamics and suggest that pharmacological MFN inhibition may provide a new therapeutic strategy to limit cardiac damage during reperfused myocardial infarction.
    DOI:  https://doi.org/10.1038/s44161-026-00903-6
  5. J Am Chem Soc. 2026 Sep 23. 148(37): 40556-40567
      Mitochondrial inner-membrane ultrastructure plays a central role in cellular metabolism, aging, and cell death. However, super-resolution imaging of mitochondria after fixation remains challenging: commercially available fixable probes often lack sufficient reactivity for strong retention during fixation, whereas state-of-the-art probe PKMO FX, despite high fixation efficiency, suffers from low cellular permeability due to the introduction of highly hydrophilic groups. Here, we overcome this "permeability-fixability trade-off" by introducing a rational design strategy centered on amide-to-ester substitution. We report mitochondrial probes, PK Mito 590 FIX and PK Mito 647 FIX, which leverage optimized lipophilic ester linkages to achieve rapid mitochondrial labeling kinetics (labeling within 10 min) and superior aldehyde cross-linking efficiency (>90% signal retention). This molecular engineering enables a seamless transition from live-cell dynamics to post-fixation super-resolution microscopy with unprecedented signal-to-background ratios. Crucially, the enhanced permeability of these probes unlocks post-fixation imaging of multicellular samples, allowing the visualization of mitochondrial architectures within patient-derived cell clusters and isolated mouse islets. Furthermore, we demonstrate that these probes withstand the harsh polymerization conditions of expansion microscopy (ExM), democratizing mitochondrial ultrastructural imaging via standard confocal platforms. Collectively, this toolkit bridges the gap between physiological dynamics and structural definition, offering a versatile platform for multiscale interrogation of mitochondrial biology in both adherent cells and complex multicellular systems.
    DOI:  https://doi.org/10.1021/jacs.6c16881
  6. Nat Commun. 2026 09 28. pii: 11175. [Epub ahead of print]17(1):
      ClpP protease maintains proteostasis in human mitochondria and is overexpressed in cancers such as acute myeloid leukemia (AML). While activators such as dordaviprone (ONC201) have reached the clinic, the development of ClpP inhibitors has been hampered by paradoxical activation upon orthosteric inhibitor binding. Here, we report a series of quinazolinone-based compounds that allosterically inhibit human ClpP with nanomolar potency. Cryo-EM and H/D exchange mass spectrometry reveal that our lead compound binds sub-stoichiometrically to a distal hydrophobic pocket ~30 Å from the active sites, disrupts a conserved inter-subunit cluster, and induces a conformational change that misaligns the catalytic triad, thereby inactivating ClpP. The binding site of our quinazolinone-based inhibitors partially overlaps with that of the activator dordaviprone. In a xenograft mouse model of leukemia, our lead compound significantly reduced tumor burden following short-term oral administration. Our findings identify a regulatory hotspot in human ClpP and a mechanistically distinct inhibition strategy.
    DOI:  https://doi.org/10.1038/s41467-026-78140-5
  7. Mol Neurobiol. 2026 Oct 28. pii: 997. [Epub ahead of print]63(1):
      The brain, as a highly metabolically active organ, depends on mitochondrial oxidative phosphorylation (OXPHOS) to sustain energy demands. When mitochondrial function is impaired, cells undergo metabolic reprogramming toward aerobic glycolysis, leading to lactate accumulation. Beyond its traditional role as a metabolic byproduct, lactate is now recognized as a signaling molecule that links metabolism to epigenetic regulation through protein lactylation, a post-translational modification identified by Zhang et al. in 2019. Research on lactylation has progressed through three stages: initial discovery in histone lactylation as an epigenetic mark, expansion to non-histone proteins revealing roles in metabolic and structural regulation, and recent identification of mitochondrial protein lactylation influencing OXPHOS, the tricarboxylic acid (TCA) cycle, and reactive oxygen species (ROS) production. This review summarizes the mitochondrial-lactate-lactylation axis in the nervous system, including brain lactate metabolism, the astrocyte-neuron lactate shuttle, and regulatory mechanisms of lactylation (writers, erasers, and readers). We further discuss its roles in histone and non-histone modification, its bidirectional relationship with mitochondrial dysfunction, and its involvement in neurodegenerative, cerebrovascular, and neuropsychiatric disorders. Finally, we highlight the therapeutic potential of targeting lactylation pathways. Collectively, mitochondrial lactate signaling and protein lactylation emerge as a central link between metabolic reprogramming and epigenetic dysregulation in neurological diseases, providing new avenues for therapeutic intervention.
    Keywords:  Epigenetics; Lactylation; Metabolic reprogramming; Mitochondria; Neurological disorders; Oxidative phosphorylation
    DOI:  https://doi.org/10.1007/s12035-026-06291-z
  8. Nat Commun. 2026 Sep 30. pii: 11255. [Epub ahead of print]17(1):
      Successful cancer immunotherapy requires not only tumor cell killing but also the activation of innate and adaptive immune responses. The inhibitor of apoptosis (IAP) proteins cIAP1, cIAP2 and XIAP act as key suppressors of RIPK1-driven immunogenic cell death, thereby enabling tumor immune evasion and limiting the effectiveness of immune checkpoint blockade (ICB). ASTX660 (tolinapant) is a non-peptidomimetic antagonist with a balanced activity against all clinically relevant IAPs, designed to lower the TNF cytotoxicity threshold and sensitize tumors to T cell-mediated killing. Here, we present results from the phase I ASTEROID trial (NCT05082259), evaluating ASTX660 in combination with pembrolizumab in patients with advanced solid tumors. Primary endpoints were recommended phase 2 dose (RP2D) and safety, while secondary endpoints were anti-tumor activity and pharmacokinetics. The combination was well tolerated and demonstrated early evidence of efficacy. RP2D was ASTX660 150 mg (7-days-on/14-days-off) with pembrolizumab. Overall response rate was 33%, including responses in ER⁺ breast cancers typically resistant to ICB. Integrated translational analyses reveal that response is associated with a TNF/IFN-enriched inflammatory tumor microenvironment, increased tumor antigenicity and enhanced TCR clonal diversity, whereas resistance correlates with a CCR4/6/7/8-driven TAM/Treg-dominant niche. Together, these results provide clinical proof-of-concept that dual IAP and PD-1 blockade sensitize tumors, while identifying candidate biomarkers to guide patient stratification in future studies.
    DOI:  https://doi.org/10.1038/s41467-026-77552-7
  9. Nature. 2026 Oct 28.
      The neural plasticity that underlies adaptation and learning requires countervailing homeostatic mechanisms to maintain the stability and responsiveness of neural circuits. Previous work has described several forms of synaptic homeostasis1, but the mechanisms that detect changes in activity and transduce these into altered neurotransmission have remained poorly understood. Here we show that high-frequency stimulation alters the subsequent properties of neurotransmitter release to confer a presynaptic form of homeostasis, independent of postsynaptic receptors. The mechanism involves vesicular SNARE protein (v-SNARE) VAMP7 (vesicle-associated membrane protein 7), which reduces neurotransmitter release by inhibiting the entry of Ca2+ specifically through P/Q-type presynaptic Ca2+ channels. Previous work has implicated target SNARE proteins (t-SNAREs) in the inhibition of Ca2+ channels2, but without clear physiological rationale. We show that the activity-dependent regulation of release mediated by VAMP7 requires the t-SNARE syntaxin. Although VAMP7 acts at the plasma membrane to inhibit P/Q-type channels, it localizes predominantly to a subset of synaptic vesicles made by adaptor protein-3 (AP-3) that respond specifically to high-frequency stimulation3,4. The localization of VAMP7 to AP-3-derived synaptic vesicles thus provides a mechanism for the activity-dependent delivery of VAMP7 to the plasma membrane, where it associates with syntaxin to inhibit P/Q-type Ca2+ channels and transmitter release. This homeostatic form of metaplasticity operates at multiple excitatory synapses, and in its absence, the fraction of FOS+ neurons increases several fold, revealing a general property of excitatory neurotransmission that might also maintain the sparsity of neural connections.
    DOI:  https://doi.org/10.1038/s41586-026-11201-3
  10. Cell Mol Life Sci. 2026 Aug 26. pii: 395. [Epub ahead of print]83(1):
      Parkin is an E3 ubiquitin ligase and its function is primarily regulated by its phosphorylation, yet the role of Parkin ubiquitination remains unclear. Here, we identified the Parkin ubiquitination site at lysine 27 (K27) by mass spectrometry. CHX chase assay confirmed that Parkin ubiquitination-deficient mutant (K27R) exhibited the reduction of Parkin stability. Meanwhile, USP10 was validated as a deubiquitinating enzyme regulating Parkin. Importantly, the Parkin mutant also showed the impaired mitochondrial translocation and the diminished interaction with PINK1, indicating the decreased Parkin phosphorylation. Reciprocally, the Parkin phosphorylation-deficient mutant (S65A) reduced the Parkin ubiquitination level, revealing an interplay between Parkin ubiquitination and its phosphorylation. Functionally, the Parkin mutant elevated the levels of mitochondrial membrane proteins, indicating the impaired mitophagy, which subsequently triggered the release of mitochondrial DNA (mtDNA) and the activation of the cGAS‑STING pathway. Moreover, the Parkin mutant suppressed the oxidative phosphorylation while it markedly enhanced the intracellular glycolysis. Finally, the Parkin mutant promoted the tumor spheroid formation and accelerated tumor growth in vivo, demonstrating the loss of its tumor-suppressive function. Collectively, our findings revealed that Parkin ubiquitination governs its stability and its function in cervical cancer, and may serve as a potential biomarker and therapeutic target.
    Keywords:  Mitophagy; Parkin phosphorylation; Parkin ubiquitination; Tumorigenesis
    DOI:  https://doi.org/10.1007/s00018-026-06362-3
  11. Nature. 2026 Oct 28.
      The N7-methylguanosine (m7G) modification is one of the most prevalent tRNA modifications, mainly catalysed by the METTL1-WDR4 protein complex1-4. The m7G methyltransferase METTL1 has been linked to oncogenic transformation and the maintenance of several aggressive malignancies; however, the clinical implications of therapeutically targeting a tRNA-modifying enzyme have not been established. Here we present the development and characterization of STM9005, a highly selective and potent first-in-class tRNA methyltransferase inhibitor of METTL1. Treatment of numerous cancer cell models (including leukaemia, melanoma, pancreatic carcinoma, oesophageal cancer and small cell lung carcinoma) with STM9005 blocks cell growth, causes differentiation changes and dysregulates cell cycle progression. These cellular effects were accompanied by a selective decrease in m7G on a subset of tRNAs and a reduction in their expression levels, which impacted the translation of oncogenic mRNAs. We show that pharmacological inhibition of METTL1 in vivo impairs tumour growth and significantly prolongs survival in multiple mouse cancer models of different tissue origin. Collectively, our results provide a strong proof of concept that targeting of tRNA methylation is a promising avenue of anti-cancer therapy and illustrate that catalytic inhibition of METTL1 represents a therapeutic strategy against a number of aggressive malignancies.
    DOI:  https://doi.org/10.1038/s41586-026-11178-z
  12. Cardiovasc Res. 2026 Oct 26. pii: cvag240. [Epub ahead of print]
       AIMS: Dysregulation of NOR-1 has been reported in cardiovascular diseases associated with altered calcium handling. We therefore investigated how NOR-1 affects calcium homeostasis and arrhythmogenesis to identify the underlying mechanisms.
    METHODS: We assessed the expression of NOR-1 and calcium regulatory proteins in myocardial samples from humans and mice that overexpress human NOR-1 in the heart (TgNOR-1). Gene promoter activity was determined by transient co-transfection assays. Calcium imaging, patch-clamp recordings and immunofluorescent labeling was performed in mouse cardiomyocytes. Experimental data were used for mathematical modeling. Arrhythmias were induced in vivo by an epinephrine/caffeine challenge.
    RESULTS: In human cardiac samples, mRNA levels of genes coding for SERCA2a, CASQ2, TN-C1 and PLB correlated with those of NOR-1, while TgNOR-1 mice exhibited higher cardiac levels of these calcium regulatory proteins than wild-type animals (WT). NOR-1 increased luciferase activity driven by the proximal promoter of both human and mouse genes. Calcium transients were smaller in TgNOR-1 cardiomyocytes while L-type calcium current and SR calcium content were unchanged. Mathematical modeling revealed that more calcium binds to CASQ2 and is released from the SR in TgNOR-1 cardiomyocytes, but the resulting calcium transient is smaller because more calcium is buffered by TN-C1. Furthermore, NOR-1 transgenesis increased the level of reactive oxygen species and CAMKII oxidation, as well as RyR2 phosphorylation at Ser-2814, which led to a higher incidence of calcium waves and afterdepolarizations in resting TgNOR-1 cardiomyocytes. In electrically paced myocytes, NOR-1 transgenesis promoted extra-transients at low frequencies and calcium alternans at high frequencies. Importantly, these derangements in intracellular calcium handling concurred with a dramatic increase in epinephrine/caffeine-induced bidirectional ventricular tachycardia in TgNOR-1 mice. Moreover, the antioxidant N-acetylcysteine and the CAMKII inhibitor KN-93 attenuated arrythmia in TgNOR-1 mice and arrhythmogenic calcium release in isolated myocytes.
    CONCLUSIONS: Our findings highlight NOR-1 as an upstream regulator of CAMKII-oxidation underlying arrhythmia induced by defective calcium homeostasis, pointing to therapies targeting CAMKII as a means to attenuate arrhythmia triggered by pathological upregulation of NOR-1.
    DOI:  https://doi.org/10.1093/cvr/cvag240
  13. NEJM AI. 2026 Feb;3(2): AIp2501266
      AbstractArtificial intelligence (AI) tools increasingly support clinical decision-making, yet they embed hidden value frameworks that shape recommendations in ways neither physicians nor patients can anticipate. These systems may prioritize different, sometimes conflicting, objectives: maximizing revenue versus minimizing costs, respecting patient autonomy versus preventing harm, or favoring aggressive intervention versus conservative management. This consensus statement from the Responsible AI for Social and Ethical Healthcare (RAISE) symposium identifies a critical gap in current AI governance: Although model cards and regulatory guidelines describe technical specifications and broad principles, they fail to disclose the clinical values embedded in actual recommendations. Drawing on clinical scenarios where both human experts and large language models demonstrate divergent value-based decisions, we propose a "Values In the Model" (VIM) framework. The VIM is a transparent labeling system that documents how AI systems navigate value-laden clinical trade-offs. Rather than relying on electronic health record data that may perpetuate institutional biases, we recommend developing rigorous benchmarks of clinical scenarios tested against diverse stakeholder perspectives. The VIM would enable health care systems, regulators, and patients to make informed choices about AI alignment with their priorities, transforming hidden commitments into explicit, accountable ones. No existing organization currently possesses the combination of technical expertise, clinical knowledge, ethical standing, and stakeholder representation needed to steward such an effort comprehensively. We therefore call for parallel tracks: public debate on values in medical AI and carefully monitored pilot projects in leading health care systems. Without transparency into embedded values, AI risks entrenching the priorities of developers, payers, or providers at scale. With it, we can build systems that reflect the diverse values that make medicine not only a science but a fundamentally human practice.
    DOI:  https://doi.org/10.1056/AIp2501266
  14. iScience. 2026 Nov 20. 29(11): 117942
      Cancer cells exploit oxidative phosphorylation (OXPHOS) for growth and metastasis. NDUFS1, the largest subunit of the electron transport chain complex I, is a promising therapeutic target in cancer but has a context-dependent role. Here, we elucidate the function of NDUFS1 in breast cancer. Elevated NDUFS1 expression was associated with advanced breast cancer stage and poor survival outcomes. In vitro experiments showed that NDUFS1 knockdown inhibited breast cancer cell proliferation, invasion, and stemness-associated properties, whereas NDUFS1 overexpression enhanced these phenotypes. Moreover, NDUFS1 directly regulated mitochondrial respiratory function in breast cancer cells and increased c-Myc expression via PROX1. In a mouse model of breast cancer, NDUFS1 knockdown in injected mammary carcinoma cells or OXPHOS inhibition decreased tumor growth and PROX1 and c-Myc expression. Our study highlights the role of the NDUFS1-PROX1-c-Myc axis in breast cancer progression, paving the way for new therapies targeting breast cancer mitochondrial OXPHOS.
    Keywords:  NDUFS1; breast cancer; c-Myc; mitochondrial respiration; prox1
    DOI:  https://doi.org/10.1016/j.isci.2026.117942
  15. Proc Natl Acad Sci U S A. 2026 Nov 03. 123(44): e2618489123
      Cooperativity of residue interactions is prevalent in proteins and plays an essential role in protein folding. However, whether cooperativity exists in intrinsically disordered proteins (IDPs) and their assembled biomolecular condensates remains elusive. Here, we reveal the presence of residue interaction cooperativity in various IDP condensates using atomistic molecular dynamics simulations. In all these condensates, cooperative residue interactions manifest as packing between finite residue motifs (3 to 5 residues) with lifetimes three orders of magnitude longer than residue contacts. Notably, these higher-order interactions (HOIs) exhibit a significant nonadditive free energy, which originates from a local low-dielectric environment. The underlying sequence patterns like "Y-X-Q", "D-X-R", and "S-Y-X" are identified. Furthermore, HOIs dominate the cohesive energy of IDPs and condensates can be treated as HOI-crosslinked networks. This model can successfully reproduce experimental results of condensate physical properties, including saturation concentration, viscoelasticity, and interfacial tension.
    Keywords:  atomistic simulation; biomolecular condensate; cooperativity; higher-order residue interactions; physical property
    DOI:  https://doi.org/10.1073/pnas.2618489123
  16. Nat Chem Biol. 2026 Oct 30.
      Heterotrimeric G proteins, activated by G-protein-coupled receptors (GPCRs), are central mediators of cellular signaling. Activation requires GDP release from the Gα subunit, a step attributed largely to the C-terminal α5 helix, the primary GPCR-interacting region. Contributions from other Gα regions have remained unclear. Here we show that the N-terminal helix (αN) of Gαs promotes GDP release through a rotational conformational change. Diffracted X-ray tracking revealed that engagement with an active GPCR increases αN conformational displacement. Biochemical assays and molecular dynamics simulations showed that counterclockwise rotation of αN, viewed from the extracellular side, facilitates GDP release, whereas clockwise rotation does not. Mechanistically, this αN-mediated pathway acts synergistically with α5 conformational changes and propagates through the β-sheet network within the Ras homology domain to the P-loop and the αG helix. These findings identify an αN-driven activation pathway and extend the mechanistic framework for GPCR-triggered G protein activation.
    DOI:  https://doi.org/10.1038/s41589-026-02359-y